Letrozol Abz

Letrozole, the active ingredient in Letrozol Abz, is an aromatase inhibitor presented as a tablet for oral use. It is employed to treat hormone receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozol Abz as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozol Abz acts on estrogen‑dependent breast cancer pathways and is indicated for several clinical scenarios. - Hormone receptor‑positive breast cancer (postmenopausal): Reduces estrogen production to inhibit tumor growth. - Adjuvant treatment of early‑stage breast cancer (postmenopausal): Lowers the risk of disease recurrence after surgery. - Metastatic breast cancer (postmenopausal): Delays disease progression and extends survival.

Adverse reactions may occur with letrozole therapy and are categorized by frequency.

Common Side Effects: - Hot flashes: Sudden feeling of warmth, often with sweating. - Arthralgia: Joint pain or stiffness. - Fatigue: Persistent tiredness unrelated to activity. - Nausea: Mild to moderate upset stomach. - Headache: Tension‑type or migraine‑like pain. - Insomnia: Difficulty initiating or maintaining sleep.

Serious or Rare Side Effects: - Severe liver injury: Jaundice, elevated transaminases. - Bone fracture: Increased risk due to reduced bone mineral density. - Deep vein thrombosis or pulmonary embolism: Swelling, pain, or shortness of breath. - Anaphylaxis: Rapid onset of rash, airway swelling, or hypotension. - QT interval prolongation: Potential cardiac arrhythmias. - Severe allergic reaction: Skin rash, itching, or swelling.

Patients should be monitored for specific safety considerations before and during letrozole therapy. - Bone health monitoring: Assess bone mineral density periodically to detect osteoporosis. - Liver function testing: Perform baseline and periodic liver enzyme assessments. - Cardiovascular risk evaluation: Review history of thromboembolic events. - Hot flash management: Counsel patients on lifestyle measures and possible supportive therapy. - Pregnancy avoidance: Ensure effective contraception; letrozole is contraindicated in pregnancy. - Store at room temperature: Keep in the original container, protect from moisture and direct sunlight.

Letrozole may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Estrogen‑containing hormone therapy: Counteracts letrozole’s estrogen‑lowering effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): May markedly reduce plasma concentrations. - Potent CYP2C19 inhibitors (e.g., fluconazole): Can increase exposure and risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: May enhance anticoagulant effect; monitor INR closely. - Antacids containing aluminum or magnesium: May affect absorption; separate administration by at least 2 hours. - CYP2D6 substrates (e.g., tamoxifen): Potential for altered metabolism; clinical significance uncertain.